Healthcare's budget plan leans on Medicare beneficiaries

Healthcare industry leaders are poised to make their own deficit-reduction suggestions--including some that might not win them points in a popularity contest. Uncertain what budget cuts the deficit-reduction committee might propose, the Healthcare Leadership Council has come up with its own proposal that would ask Medicare beneficiaries to endure more belt-tightening themselves, the Wall Street Journal reports.

The group is aiming to put forward an alternative more palatable than across-the-board Medicare cuts mandated by the deficit-reduction bill if the "supercommittee" doesn't agree on its own plan. And it's betting that its proposal will be easier to bear than budget-cutting ideas floated in the past, such as drug re-importation.

The council, which includes Big Pharma executives, hospital companies and insurers, crafted a plan that would raise the Medicare-eligibility age little by little to 67 from 65, beginning in 2014. It would hike co-pays and deductibles. It would require well-off seniors to pay higher premiums. And it would add private-sector competition to traditional Medicare coverage, pitting government-subsidized private insurance plans against regular Medicare.

Requiring seniors to pay more might be considered a non-starter; after all, consumer groups, particularly AARP, have vociferously fought against such moves in the past. But the council figures that provider-based Medicare cuts will end up costing beneficiaries when all is said and done. "This thinking that we're protecting beneficiaries because we're only cutting providers--that's mythical," said Mary Grealy, the council's president, according to the WSJ. "At some point it does affect beneficiaries."

- read the WSJ story

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.